A randomized control trial on the postoperative application of gemcitabine in patients with radical resection of biliary tract cancers

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-09000477

Enrollment

Unknown

Registered

2009-08-03

Start date

2009-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer

Interventions

Group A:Gemcitabine

Group B:Gemcitabine+5-Fu

Group C:Gemcitabine+Oxaliplatin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female without age restrict; 2. The patients with biliary tract cancer who had undergone radical resection.

Exclusion criteria

Exclusion criteria: The patients who can not endure chemotherapy.

Design outcomes

Primary

Measure	Time frame
Overall survival rate;	—

Secondary

Measure	Time frame
Recurrence rate;Quality of life;	—

Countries

China

Contacts

Public ContactJie Wang

sumsjw@yahoo.com.cn+86 13802900227

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026